Top-News
Kapitalmärkte USA

Sonnet Biotherapeutics News

Aktie
WKN:  A3EUBF ISIN:  US83548R3030 US-Symbol:  SONN
1,80 $
+0,00 $
0,00%
10.05.24 17:26:28
Handeln Depot/Watchlist
Aktienanzahl *
1,75 Mio.
Marktkapitalisierung *
2,66 Mio. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 05.09.2023

Sonnet Biotherapeutics News

09.01.23 - PR Newswire
Thinking about buying stock in SWVL Holdings, Apexigen, Sonnet BioTherapeutics, Spruce Biosciences, or Tilray?
Thinking about buying stock in SWVL Holdings, Apexigen, Sonnet BioTherapeutics, Spruce Biosciences, or Tilray? PR Newswire
02.11.22 - PR Newswire
Thinking about buying stock in Mullen Automotive, Xpeng, Paramount Global, Devon Energy, or Sonnet BioTherapeutics?
Thinking about buying stock in Mullen Automotive, Xpeng, Paramount Global, Devon Energy, or Sonnet BioTherapeutics? PR Newswire
01.11.22 - PR Newswire
Thinking about buying stock in SoFi Technologies, Trip.com, Sonnet BioTherapeutics, Lyft, or Nio?
Thinking about buying stock in SoFi Technologies, Trip.com, Sonnet BioTherapeutics, Lyft, or Nio? PR Newswire
31.10.22 - PR Newswire
Thinking about buying stock in Meta Platforms, Dominion Energy, Roku, Quanergy Systems, or Sonnet BioTherapeutics?
Thinking about buying stock in Meta Platforms, Dominion Energy, Roku, Quanergy Systems, or Sonnet BioTherapeutics? PR Newswire
21.09.22 - ACCESSWIRE
Sonnet BioTherapeutics Announces Progress in Two Phase 1 Dose-Escalation Trials of SON-1010
The SB101 and SB102 studies have together dosed 19 subjects to date This early review of safety sets the stage for further dose escalation Additional safety and cytokine-​specific ...
16.09.22 - PR Newswire
Thinking about buying stock in Sonnet BioTherapeutics, Bank of America, Intel Corp, Cisco Systems, or Meta?
Thinking about buying stock in Sonnet BioTherapeutics, Bank of America, Intel Corp, Cisco Systems, or Meta? PR Newswire
16.09.22 - ACCESSWIRE
Sonnet BioTherapeutics Announces 1-for-14 Reverse Stock Split
PRINCETON, NJ / ACCESSWIRE / September 16, 2022 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company ...
15.09.22 - PR Newswire
Thinking about buying stock in Nabriva Therapeutics, Sonnet BioTherapeutics, Fast Radius, Volcon, or Velo3D?
Thinking about buying stock in Nabriva Therapeutics, Sonnet BioTherapeutics, Fast Radius, Volcon, or Velo3D? PR Newswire
14.09.22 - PR Newswire
Thinking about buying stock in Cisco Systems, Sonnet BioTherapeutics, Nikola Corp, Baudax Bio, or Amyris?
Thinking about buying stock in Cisco Systems, Sonnet BioTherapeutics, Nikola Corp, Baudax Bio, or Amyris? PR Newswire
15.08.22 - ACCESSWIRE
Sonnet BioTherapeutics Provides Fiscal Year 2022 Third Quarter Business and Earnings Update
Initiation of two clinical trials of SON-1010 in both healthy volunteers and patients with advanced solid tumors Positive preclinical data of SON-1010 combined with anti-PD1 ...
22.07.22 - ACCESSWIRE
Sonnet BioTherapeutics Announces Clinical Trial of SON-080 in Patients with Persistent Chemotherapy-Induced Peripheral Neuropathy
Sonnet's first clinical trial with SON-080 is a Phase 1b/2a double-​blind, randomized controlled trial This trial is expected to provide safety data compared to previous IL-6 products, ...
21.07.22 - ACCESSWIRE
Sonnet BioTherapeutics Announces Clinical Trial of SON-1010 in Healthy Volunteers
Represents Sonnet's second clinical trial with SON-1010 Study expected to provide important PK and PD data for potential additional indications of interest Recruitment initiated ...
10.06.22 - PR Newswire
Thinking about buying stock in Applied UV, Sonnet BioTherapeutics, Spirit Airlines, Rigel Pharmaceuticals, or SeaChange?
Thinking about buying stock in Applied UV, Sonnet BioTherapeutics, Spirit Airlines, Rigel Pharmaceuticals, or SeaChange? PR Newswire
09.06.22 - PR Newswire
Thinking about buying stock in Bluejay Diagnostics, Sonnet BioTherapeutics, SeaChange International, Rekor Systems, or Aldeyra Therapeutics?
Thinking about buying stock in Bluejay Diagnostics, Sonnet BioTherapeutics, SeaChange International, Rekor Systems, or Aldeyra Therapeutics? PR Newswire
09.06.22 - ACCESSWIRE
Sonnet BioTherapeutics Announces Positive Results from a Preclinical Combination Study of SON-1010 with anti-PD1 Checkpoint Inhibition
Tumor volume growth inhibition improvements observed with the combination of SON-1010 (IL12-F H AB) and a commercially available anti-PD1 antibody Combination of SON-...
02.06.22 - ACCESSWIRE
Sonnet BioTherapeutics Announces Adjournment of Annual Meeting Due to Lack of Quorum
PRINCETON, NJ / ACCESSWIRE / June 2, 2022 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing ...
10.05.22 - ACCESSWIRE
Sonnet BioTherapeutics Provides Fiscal Year 2022 Second Quarter Business and Earnings Update
IND for SON-1010 cleared by FDA with first patient dosed in trial for advanced solid tumors SON-080 on track to begin clinical studies by mid-2022 Preclinical data for SON-1010, ...
13.04.22 - PR Newswire
Thinking about buying stock in Aterian, Sonnet BioTherapeutics, Gap, Uranium Energy, or Sunshine Biopharma?
Thinking about buying stock in Aterian, Sonnet BioTherapeutics, Gap, Uranium Energy, or Sunshine Biopharma? PR Newswire
13.04.22 - ACCESSWIRE
Sonnet BioTherapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of SON-1010 for Advanced Solid Tumors
PRINCETON, NJ / ACCESSWIRE / April 13, 2022 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-​stage company developing targeted immunotherapeutic drugs, ...
08.04.22 - ACCESSWIRE
Sonnet BioTherapeutics Announces Preclinical Data Supporting Its Bispecific Interleukin Candidates at the American Association for Cancer Research (AACR) 2022 Annual Meeting
PRINCETON, NJ / ACCESSWIRE / April 8, 2022 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-​stage company developing targeted immunotherapeutic drugs, ...

Newssuche

Videos

newspaper
17.05.24 -4,89%
Technical Trading: Gold Long-​Chance
Gold Long Typ: Turbo Open End WKN: VD1G7Y Hebel: 10 Laufzeit: OpenEnd Einstieg: Market ... Mehr »